Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

S. Abdelwahab



Author of

  • +

    P1.09 - Poster Session 1 - Combined Modality (ID 212)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Combined Modality
    • Presentations: 1
    • +

      P1.09-018 - Pemetrexed and carboplatin concomitant with Thoracic Radiotherapy in Treatment of elderly patients with non- squamous Non Small cell lung Cancer (NSCLC): Institutional Experience (ID 2415)

      09:30 - 09:30  |  Author(s): S. Abdelwahab

      • Abstract

      Background
      Concomitant chemoradiotherapy is the standard treatment of unresectable stage IIIA/IIIB non- small cell lung cancer (NSCLC). However, the optimal chemotherapy regimen is still controversial. Therefore; we conducted this prospective clinical trial to evaluate the efficacy and safety of pemetrexed and carboplatin when given concomitantly with thoracic radiotherapy followed by consolidation therapy of pemetrexed and carboplatin in elderly patients with locally advanced non-squamous NSCLC

      Methods
      Thirty seven patients with previously untreated, unresectable stage IIIA or IIIB non-squamous NSCLC with ECOG PS of ≤2, ≥65years old, and had adequate organs functions were enrolled into the study between August 2010 and April 2013. Patients received pemetrexed 500 mg/m[2] and carboplatin area under the curve (AUC) 5 on day 1 repeated every 3 weeks concomitant with thoracic radiotherapy 60-66 Gy over 6-6.5 weeks, followed by pemetrexed and carboplatin for 3 cycles as consolidation therapy. Treatment response, toxicity, progression free survival and overall survival were evaluated.

      Results
      The median age was 71 (range 65-79). Twenty seven patients (73%) were men. Twenty four patients (65%) had Stage IIIB and 13 patients (35%) had stage IIIA. Performance status was measured by ECOG and it was 0 in 23 patients (62%), 1-2 in 14 patients (38%). Eight (22%) patients had a complete response, 22 (59%) patients had partial response, while 5 (14%) patients had a stable disease and 2 (5%) patients had a progressive disease. The overall response rate (81%, 95% confidence interval (CI): 68-96%).The median PFS was 11 months (95% CI: 9.8-12.9 months).Grade 3/4 toxicity were reported as neutropenia in 12 (32%) patients; thrombocytopenia in 9 (24%) patients; anemia in 7 (19%) patients; vomiting in 3 (8%) patients; dysphagia in 2 (5%) patients, radiation pneumonitis in 2 (5%) patients and fatigue in 3 (8%) patients. No treatment related deaths (neither due to sepsis nor bleeding) were reported in the study.

      Conclusion
      Concomitant chemoradiotherapy using full doses of pemetrexed and carboplatin for treatment of elderly patients with locally advanced non-squamous NSCLC is a safe and effective regimen and it needs enrolling more patients to confirm the current results.

  • +

    P1.10 - Poster Session 1 - Chemotherapy (ID 204)

    • Event: WCLC 2013
    • Type: Poster Session
    • Track: Medical Oncology
    • Presentations: 1
    • +

      P1.10-049 - Efficacy of bevacizumab combined with paclitaxel and carboplatin: A second line treatment of elderly patients with advanced non-small cell carcinoma (NSCLC) (ID 2938)

      09:30 - 09:30  |  Author(s): S. Abdelwahab

      • Abstract

      Background
      The aim of this phase II study was to assess the efficacy and safety of paclitaxel combined with carboplatin plus bevacizumab as a second line treatment of elderly patients with advanced NSCLC.

      Methods
      Twenty one elderly patients with NSCLC who previously received only one line of chemotherapy were enrolled into this study between March 2009 and March 2013. All patients received paclitaxel 175 mg/m[2] followed by carboplatin AUC of 5, and followed by bevacizumab 15mg/kg, all agents were given via I.V infusion on day 1 and the cycle was repeated every 21 days for maximum 6-8 cycles. Patients who attained at least stable disease continued to receive single agent bevacizumab every 21 days until disease progression or unacceptable toxicity developed.

      Results
      The median age was 73 years old (range 66-82 years); 17 (81%) patients were men; ECOC PS was 0 in 4 (19%) patients, 1 in 9 (43%) patients and 2 in 8 (38%) patients. The objective response rate was 30.3%, while disease control rate was 63.7%, respectively, and the median progression-free survival time was 4. 2 months. Grade 3/4 neutropenia, grade 3/4 thrombocytopenia occurred in 2(10%) patients, while grade 3/4 peripheral neuropathy occurred in 3(14%) patients and grade 3/4 fatigue had occurred in 4(19%) patients. No treatment-related deaths had been reported in this study.

      Conclusion
      Bevacizumab when given with paclitaxel and carboplatin exhibits activity in previously treated elderly patients with advanced NSCLC and has acceptable toxicity.